PharmaBoardroom published a LinkedIn post discussing Achim Hartig and Roxane Höck discussing the shifting investment landscape in Germany and Europe.
Public source
Publisher name
Public post
US companies are pulling back on greenfield investment in Germany. They're sending more R&D instead. High tariffs mean companies must produce within the tariff zone itse…
Company
PharmaBoardroom
The ultimate resource for Healthcare & Life Sciences leaders worldwide
- Industry
- Technology, Information and Media
- Location
- Norwich, GB
- Company size
- 11–50 employees
About PharmaBoardroom
Pharma Boardroom is the ultimate resource for Healthcare & Life Sciences leaders worldwide. We're your dedicated source for in-depth insights into both local and global markets. Our teams connect with key stakeholders in person, covering every corner of the globe. We go where others don't, conducting face-to-face meetings with industry influencers to deliver unparalleled perspectives on market dynamics. Our commitment to understanding the unique challenges and opportunities in various regions sets us apart. In an ever-evolving healthcare landscape, our extensive network allows you to access firsthand experiences from peers in your local market and beyond. Thanks to our exclusive conversations with industry leaders, we help you access high-level insights. This information loop has proven crucial in shaping successful business strategies in demanding environments. With over a thousand interviews, daily updates, global market news, articles, and a comprehensive database, we are your trusted partner in navigating the regulatory landscape and optimizing business opportunities. Visit our website for more information: https://www.pharmaboardroom.com
See moreLatest activity
Latest activity from PharmaBoardroom
11 signals
Legal & Regulatory
PharmaBoardroom reports that childhood myopia now has its first approved pharmacological treatment in Europe, with Santen rolling it out fast.
Customers & Market
PharmaBoardroom reports that the treatment for childhood myopia is now available in eight countries across EMEA after launching in Germany one year earlier.
Products & Services
PharmaBoardroom reports that Madrigal Pharmaceuticals has one commercial product, Rezdiffra, which is the first treatment ever approved specifically for MASH, a liver disease where more than 20 development programmes failed before it succeeded.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Novartis Deutschland
Novartis Deutschland published an article in its LinkedIn discussing the development of digital twins based on existing health and study data to simulate disease progression and support clinical trial planning.
Research & Knowledge
Germany Trade & Invest
Germany Trade & Invest published an analysis by the German Economic Institute in Cologne registering some €86 billion in foreign investment in Germany in 2025, representing a 50 percent increase on the previous year.
Research & Knowledge
The Pharma Letter
The Pharma Letter reports that the ABPI now counts an additional £2 billion ($2.70 billion) committed since September 2025.
Research & Knowledge
GlobalData Healthcare
GlobalData Healthcare featured Frankie Fattorini speaking to experts across the continent about the most-favoured-nation pricing debate and European healthcare market access strategy.
Research & Knowledge
The Association of the British Pharmaceutical Industry (ABPI)